Literature DB >> 35464662

Antibiofilm activity and bioactive phenolic compounds of ethanol extract from the Hericium erinaceus basidiome.

Sari Darmasiwi1,2, Yaovapa Aramsirirujiwet1, Ingorn Kimkong1,3.   

Abstract

Biofilm formation has become a serious health and environmental problem. Mushrooms are now considered a valuable source of bioactive compounds with antimicrobial properties. The lion's mane mushroom (Hericium erinaceus [HE]) has been used as an antimicrobial for ulcers and gastritis in East Asian countries. However, studies on the antibiofilm activities of HE basidiome against biofilm-forming pathogenic bacteria and their bioactive compound profiles are still limited. The purpose of this study was to determine the antibiofilm activity of HE and to identify its phenolic compound profile. The HE inhibitory activities against bacterial growth and biofilm formation were performed against Pseudomonas aeruginosa, Salmonella Typhimurium, Proteus mirabilis, and Staphylococcus aureus. Remarkably, P. mirabilis was the most susceptible bacteria to HE. The total phenolic content (TPC) of HE was 1652 ± 1.06 µg/ml, with protocatechuic acid and p-coumaric acid being the most abundant phenolic compounds as determined by high-performance liquid chromatography-mass spectrophotometry (HPLC-MS). This research highlights the possibility of HE as an antibiofilm agent that can be developed as a nutraceutical and natural food preservative. Copyright:
© 2022 Journal of Advanced Pharmaceutical Technology & Research.

Entities:  

Keywords:  Biofilm; Hericium erinaceus; pathogenic bacteria; phenolic contents

Year:  2022        PMID: 35464662      PMCID: PMC9022366          DOI: 10.4103/japtr.japtr_1_22

Source DB:  PubMed          Journal:  J Adv Pharm Technol Res        ISSN: 0976-2094


INTRODUCTION

Biofilms are bacterial communities that are attached to surfaces and covered in an extracellular matrix. With the higher resistance of biofilms to antibiotics compared to planktonic forms, the treatment of infections and food contamination associated with biofilm-forming bacteria has become more challenging.[12] Current research has attempted to identify effective natural compounds for the prevention and control of biofilms. Bioactive phenolic acids have been reported to exhibit antibiofilm activities.[3] Hence, mushrooms have become a topic of interest in drug discovery as potential sources of phenolic compounds with antibiofilm activities. Several solvents have been used to extract natural antibiofilm substances.[4] The methanol extract (ME) of Mycena rosea inhibited Pseudomonas aeruginosa biofilms by up to 50%.[5] Meanwhile, the ethanol extract (EE) of Marasmius oreades had higher phenolic levels and biofilm inhibition against S. epidermidis and P. aeruginosa by up to 90%.[6] The ethyl acetate extract (EAE) of Hericium sp. WBSP8 showed antibiofilm activity against Candida albicans.[7] Previous studies have reported HE as a potential antibacterial agent, including its application to relieve gastric ulcers.[89] However, research on the antibiofilm activity of EE from HE basidiome against pathogenic biofilm-forming bacteria is still limited. It has been previously noted that ethanol as an extraction solvent displayed better antibiofilm activity. Therefore, the aims of the work were to determine the antibiofilm activity and phenolic compounds of the ethanol extract of HE basidiome, which may increase its potency as a nutraceutical or food preservative.

MATERIALS AND METHODS

Bacterial strains

The bacterial strains, Pseudomonas aeruginosa, Proteus mirabilis, Salmonella Typhimurium, and Staphylococcus aureus, were maintained in nutrient agar at 4°C for subsequent experiments.

Mushroom samples and extraction

Basidiome samples were collected from Marayat Farm, Pathumthani, Thailand, from February–March 2021 and identified at the Department of Microbiology, Kasetsart University, Thailand, as HE (Voucher No. HE-01). Basidiome samples (200 g) were cleaned and air-dried before extraction. The samples were soaked in 800 mL of 96% ethanol (1:4, w/v) for 7 days at 25°C in the dark. The extract was concentrated at 40°C in a rotary evaporator, then freeze-dried, and stored at −20°C.[10]

Disk diffusion assay

Aliquots of 100 µl bacterial suspension (108 CFU/ml) were spread onto sterile Mueller–Hinton Agar (MHA) plates. After that, 6 mm filter paper disks were impregnated with 10 µl HE (200 mg/ml) or ampicillin as a positive control in 5% DMSO. The disks were placed on MHA surfaces and incubated at 37°C for 24 h, followed by a zone of inhibition (ZOI) measurement.[11]

Biofilm quantification assay

A biofilm quantification analysis was performed using the crystal violet assay (CVA). About 200 µl of bacterial culture in Mueller–Hinton broth (108 CFU/ml) was inoculated into 96-well microplates and incubated at 37°C for 42 h. The suspensions were then discarded and rinsed with 250 µl NaCl followed by ethanol. The microplates were then dried and subsequently added to 100 µl of 0.1% crystal violet for 15 min of incubation. The stain was then excluded and rinsed with distilled water before being treated with 200 µl of 30% glacial acetic acid. The absorbance was taken at 550 nm using a microplate spectrophotometer.[6] The biofilm-forming bacteria were distinguished using the cutoff OD (ODc). The ODc is three standard deviations higher than the average of the negative control OD at 550 nm. The classifications were as follows: no biofilm producers (OD ≤ ODc), weak (O. Dc < O. D. ≤2 × ODc), moderate (2 ODc < OD ≤ (4 × ODc), and strong (4 × ODc < OD).[12]

Antibiofilm assay

In brief, a 195 µl bacterial suspension (108 CFU/ml) and 5 µl HE were added into 96-well microplates at 3.375–100 mg/ml following incubation at 37°C for 42 h. The antibiofilm activities were measured using the CVA assay by comparing the absorbance of treatments with the negative control.[7]

Total phenolic content

The total phenolic content (TPC) was calculated using Folin–Ciocalteu as described by Nowacka et al.[13]

Phenolic compound analysis using high-performance liquid chromatography-mass spectrophotometry

The HE (0.1 g/mL) was dissolved in ethanol: water (20:80) and filtered with a 0.22 µm LC disk. Aliquots of 10 µL were injected into an HPLC Agilent 1200 series with a C-18 column operated at 30°C using mobile phase: (A) 0.1% formic acid in H2O and (B) 0.1% formic acid in acetonitrile with a flow rate of 0.2 ml/min at 280 nm. The MS analysis was conducted using an Agilent 6420 according to the method by Li et al. Identification was accomplished through comparison with commercial standards and library databases.[14]

Statistical test

The experiments were repeated three times and the findings were given as mean ± standard deviation. The statistical analysis was carried out in SPSS version 22 (IBM, USA), with a significance value of P < 0.05, using one-way ANOVA followed by Duncan's multiple range test.

RESULTS AND DISCUSSION

Antibacterial activity of Hericium erinaceus

The antibacterial activities of HE against biofilm-forming bacteria are shown in Table 1. The highest ZOI was found against S. aureus (11.7 mm), followed by P. mirabilis (6 mm). It revealed that HE did not show sufficient antibacterial activity to inhibit the growth or kill the tested pathogens compared to the positive control.
Table 1

Zone of inhibition of Hericium erinaceus (mm±standard deviation)

Treatments Pseudomonas aeruginosa S. Typhimurium Proteus mirabilis Staphylococcus aureus
HE0a0a6±0a11.7±0.25a
C (+) (ampicillin)23.3±1.25b17.3±0b23.3±0.5b38.3±0.25b

Means notated by different letters differ significantly (P<0.05). HE: Hericium erinaceus

Zone of inhibition of Hericium erinaceus (mm±standard deviation) Means notated by different letters differ significantly (P<0.05). HE: Hericium erinaceus The results showed that P. aeruginosa and S. Typhimurium were considered strong biofilm producers, while P. mirabilis and S. aureus were moderate biofilm producers [Table 2].
Table 2

Classifications of biofilm-forming bacteria used in this study

Bacterial strainsGram-stainingClassification
Pseudomonas aeruginosa Gram-negativeStrong
S. Typhimurium Gram-negativeStrong
Proteus mirabilis Gram-negativeModerate
Staphylococcus aureus Gram-positiveModerate
Classifications of biofilm-forming bacteria used in this study The Gram-negative bacteria in this study were mostly classified as strong producers. Pili and natural conjugative plasmids attached to surfaces might improve the biofilm formation of Gram-negative bacteria.[15] However, both Gram bacteria may form biofilms of similar properties.[16]

Antibiofilm evaluation of Hericium erinaceus

The antibiofilm activities of HE are presented in Figure 1. In general, HE exhibited antibiofilm activities against all the tested bacteria. Therefore, although HE did not show significant antibacterial activity, it revealed antibiofilm potential. This result was similar to a study of M. oreades EE that exhibited low antibacterial effects but high antibiofilm activity against E. coli, P. aeruginosa, S. aureus, and S. epidermidis.[6]
Figure 1

Biofilm inhibition of Hericium erinaceus against (A) PA: Pseudomonas aeruginosa, (B) ST: S. Typhimurium, (C) PM: Proteus mirabilis, (D) SA: Staphylococcus aureus, Amp: Ampicillin. Means notated by different letters differ significantly (P < 0.05)

Biofilm inhibition of Hericium erinaceus against (A) PA: Pseudomonas aeruginosa, (B) ST: S. Typhimurium, (C) PM: Proteus mirabilis, (D) SA: Staphylococcus aureus, Amp: Ampicillin. Means notated by different letters differ significantly (P < 0.05) The minimum biofilm inhibitory concentration (MBIC50) of HE against P. aeruginosa was 6.25 mg/ml, while concentrations of >12.5 mg/ml were not significantly different. It might be related to P. aeruginosa resistance to HE at higher concentrations. P. aeruginosa is a Gram-negative, strong biofilm producer associated with bacteremia pneumonia and urinary tract infections (UTIs) due to its high antibiotic resistance.[617] The MBIC50 of HE against S. Typhimurium was 25 mg/ml, with significant differences at higher concentrations. S. Typhimurium is a food-borne biofilm-forming pathogen and is the causative agent of enteric fever infection.[1819] The moderate biofilm producer, P. mirabilis, is a prevalent source of respiratory, gastrointestinal, and UTIs.[20] S. aureus is a Gram-positive bacteria responsible for nosocomial and chronic wound infections.[2122] These moderate biofilm producers were shown to be more vulnerable to the antibiofilm compounds of HE with an MBIC50 of 12.5 mg/ml and a significant difference (P < 0.05) between concentration treatments. Table 3 shows the antibiofilm evaluation of HE using the CVA at higher concentrations than MBIC50 (100 mg/ml). The darker color of the wells revealed that the bacteria were strong biofilm producers. A lighter color after the treatments showed that the antibiofilm was more effective. The biofilm inhibition of HE at 100 mg/ml against P. aeruginosa and S. typhimurium was 68.81% and 68.88%, respectively, whereas for P. mirabilis and S. aureus, it was 78.18% and 70.77%, respectively. Therefore, P. mirabilis is the most susceptible strain.
Table 3

Antibiofilm evaluation of Hericium erinaceus using a crystal violet assay (100 mg/ml)

Gram stainingBacteriaC (−)HEC (+) (ampicillin)
Gram-negative Pseudomonas aeruginosa
Gram-negative S. Typhimurium
Gram-negative Proteus mirabilis
Gram-positive Staphylococcus aureus

HE: Hericium erinaceus

Antibiofilm evaluation of Hericium erinaceus using a crystal violet assay (100 mg/ml) HE: Hericium erinaceus

Bioactive phenolic compounds of Hericium erinaceus

The phenolic compounds in the HE with a potential antibiofilm effect were identified using high-performance liquid chromatography-mass spectrophotometry (HPLC-MS), as shown by the peak chromatograms, mass spectra, and identified compounds in Figures 2 and 3 and Table 4.
Figure 2

Chromatogram of high-performance liquid chromatography-mass spectrophotometry of Hericium erinaceus

Figure 3

Mass spectra (m/z) of phenolic compounds of Hericium erinaceus

Table 4

Bioactive compounds of Hericium erinaceus

RT (min)Identified compoundsm/z, (M−H)Molecular formulaContents (µg/ml)
4.663Protocatechuic acid153C7H6O4352.94±2.37
6.319p-coumaric acid163C9H8O342.05±0.05
9.633Succinic acid118C4H6O4ND
13.546Catechin derivatives289C15H14O67.96±0.20
16.1262-hydroxybenzoic acid methyl ester151C8H8O3Trace
19.946Ferulic acid193C10H10O4Trace
Total phenolic1652±1.06

ND: Not determined, RT: Retention time

Chromatogram of high-performance liquid chromatography-mass spectrophotometry of Hericium erinaceus Mass spectra (m/z) of phenolic compounds of Hericium erinaceus Bioactive compounds of Hericium erinaceus ND: Not determined, RT: Retention time The HE contained a high TPC (1652 ± 1.06 µg/ml) [Table 4], which was higher than in the HE ME from Portugal (288.25 ± 2.48 µg/100 g).[23] The HE also demonstrated different phenolic compound profiles compared to previous reports. Protocatechuic acid (352.94 µg/ml) and p-coumaric acid (42.05 µg/ml) were the major phenolic compounds of HE, while 2-hydroxybenzoic acid methyl ester and ferulic acid were found as traces. Catechin and succinic acid were also found in the extract. Previous studies found that p-coumaric acid (138.02 µg/100 g), gallic acid (76.25 µg/100 g), and p-hydroxybenzoic acid (73.99 µg/100 g) were major components in HE ME.[22] HE chloroform extract from Korea comprised ferulic acid (245.83 µg/g), 4-hydroxybenzoic acid (10.88 µg/g), and 4-coumaric acid (2.88 µg/g).[14] These variations could be attributed to the origin of the mushroom strains, cultivation conditions, and solvent used for extraction. An earlier report demonstrated that the protocatechuic acid and p-hydroxybenzoic acid of Inonotus obliquus EE contributed to antibiofilm against P. aeruginosa by affecting the bacterial flagella and pili surface attachment, particularly their swimming and twitching ability.[24] Furthermore, ferulic acid and catechin of M. oreades EE disrupted P. aeruginosa and MRSA biofilms by inhibiting the bacterial motility and physicochemical changes on the surfaces.[625] Catechin eradicated the preformed biofilm by decreasing the biomolecule production in the exopolysaccharide biofilms.[26] Succinic acid in Lentinus edodes has been reported as a weak antibiofilm against oral bacteria.[27] There have been few studies on the antibiofilm activity of edible or medicinal mushrooms. This research adds significant information about the antibiofilm of mushrooms that might be useful for health, environmental, and industrial applications.

CONCLUSION

The ethanol extract of HE basidiome had potential antibiofilm activities against pathogenic bacteria, with P. mirabilis being the most susceptible. In the HE basidiome, proteocatechuic acid and p-coumaric acid were the major phenolic compounds.

Financial support and sponsorship

Faculty of Science, Kasetsart University, Thailand; International SciKU Branding (ISB), Faculty of Science, Kasetsart University; Kasetsart University Research and Development Institute (KURDI) and the Agricultural Research Development Agency (Public Organization).

Conflicts of interest

There are no conflicts of interest.
  20 in total

1.  Natural conjugative plasmids induce bacterial biofilm development.

Authors:  J M Ghigo
Journal:  Nature       Date:  2001-07-26       Impact factor: 49.962

2.  Components in Lentinus edodes mushroom with anti-biofilm activity directed against bacteria involved in caries and gingivitis.

Authors:  Adele Papetti; Caterina Signoretto; David A Spratt; Jonathan Pratten; Peter Lingström; Egija Zaura; Itzhak Ofek; Michael Wilson; Carla Pruzzo; Gabriella Gazzani
Journal:  Food Funct       Date:  2018-06-20       Impact factor: 5.396

3.  The activity of ferulic and gallic acids in biofilm prevention and control of pathogenic bacteria.

Authors:  Anabela Borges; Maria J Saavedra; Manuel Simões
Journal:  Biofouling       Date:  2012       Impact factor: 3.209

4.  Anti-Helicobacter pylori activity of bioactive components isolated from Hericium erinaceus.

Authors:  Jian-Hui Liu; Liang Li; Xiao-Dong Shang; Jun-Ling Zhang; Qi Tan
Journal:  J Ethnopharmacol       Date:  2015-09-11       Impact factor: 4.360

5.  Antioxidant, Anticancer, Antimicrobial, and Antibiofilm Properties of the Culinary-Medicinal Fairy Ring Mushroom, Marasmius oreades (Agaricomycetes).

Authors:  Naznoosh Shomali; Okan Onar; Basar Karaca; Nergiz Demirtas; Arzu Coleri Cihan; Ilgaz Akata; Ozlem Yildirim
Journal:  Int J Med Mushrooms       Date:  2019       Impact factor: 1.921

6.  Wild mushroom extracts as inhibitors of bacterial biofilm formation.

Authors:  Maria José Alves; Isabel C F R Ferreira; Inês Lourenço; Eduardo Costa; Anabela Martins; Manuela Pintado
Journal:  Pathogens       Date:  2014-08-06

Review 7.  Developing natural products as potential anti-biofilm agents.

Authors:  Lan Lu; Wei Hu; Zeru Tian; Dandan Yuan; Guojuan Yi; Yangyang Zhou; Qiang Cheng; Jie Zhu; Mingxing Li
Journal:  Chin Med       Date:  2019-03-20       Impact factor: 5.455

8.  Potential Activity of Albino Grifola frondosa Mushroom Extract against Biofilm of Meticillin-Resistant Staphylococcus aureus.

Authors:  Teresa Fasciana; Maria Letizia Gargano; Nicola Serra; Elena Galia; Ignazio Arrigo; Maria Rita Tricoli; Orazia Diquattro; Giuseppa Graceffa; Salvatore Vieni; Giuseppe Venturella; Anna Giammanco
Journal:  J Fungi (Basel)       Date:  2021-07-10

Review 9.  Biofilm patterns in gram-positive and gram-negative bacteria.

Authors:  Rohit Ruhal; Rashmi Kataria
Journal:  Microbiol Res       Date:  2021-07-23       Impact factor: 5.415

Review 10.  Proteus mirabilis Biofilm: Development and Therapeutic Strategies.

Authors:  Reham Wasfi; Samira M Hamed; Mai A Amer; Lamiaa Ismail Fahmy
Journal:  Front Cell Infect Microbiol       Date:  2020-08-14       Impact factor: 5.293

View more
  1 in total

1.  Hericium erinaceus Mycelium Ameliorates In Vivo Progression of Osteoarthritis.

Authors:  Shang-Yu Yang; Chi-Jung Fang; Yu-Wen Chen; Wan-Ping Chen; Li-Ya Lee; Chin-Chu Chen; Yen-You Lin; Shan-Chi Liu; Chun-Hao Tsai; Wei-Chien Huang; Yang-Chang Wu; Chih-Hsin Tang
Journal:  Nutrients       Date:  2022-06-23       Impact factor: 6.706

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.